Alendronate (ALD), one among the nitrogen-containing bisphosphonates (NBPs), is currently used for the treatment of many pathological conditions. Unfortunately, although generally tolerated, NBPs treatment has been associated with central nervous system (CNS) adverse outcomes, such as amnesia, hallucinations and visual disturbances. So, we analyzed the effect of ALD treatment in glial cells, the main sources of cholesterol for neurons and principal cells involved in the immunological defense of the brain. We treated a glial cell line (U87-MG) with increasing doses of ALD (0.1, 1, 10, 25, 50 μM) for 48 h, aimed at evaluating the influence of this drug treatment on IL-1B expression, NLRP3 and CASP1 expression, mitochondrial activity and apoptotic cell death. We observed that ALD treatment, at the higher concentrations, induced a significant increase of IL-1B, NLRP3, CASP1 expression, provoked apoptosis and also mitochondrial damage in U87-MG. Considering the reported CNS adverse outcomes of NBPs treatment, our results confirm ALD side-effects on glial cell model.
This is a preview of subscription content, log in to check access.
This work was supported by a grant from the Institute for Maternal and Child Health IRCCS “Burlo Garofolo” (RC 42/11). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
Granovsky-Grisaru S, Belmatoug N, vom Dahl S et al (2011) The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 156:3–8CrossRefPubMedGoogle Scholar
Kleiner G, Celsi F, Tricarico PM et al (2013) Systemic and neuronal inflammatory markers in a mouse model of mevalonate kinase deficiency: a strain-comparative study. In Vivo 27:715–722PubMedGoogle Scholar
Lesclous P, Abi Najm S, Carrel JP et al (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45:843–852CrossRefPubMedGoogle Scholar
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408CrossRefPubMedGoogle Scholar
Loeb JA (1998) Functional improvement in a patient with cerebral calcinosis using a bisphosphonate. Mov Disord 13:345–349CrossRefPubMedGoogle Scholar
Loeb JA, Sohrab SA, Huq M et al (2006) Brain calcifications induce neurological dysfunction that can be reversed by a bone drug. J Neurol Sci 243:77–81CrossRefPubMedGoogle Scholar
Massa LF, Bradaschia-Correa V, Arana-Chavez VE (2006) Immunocytochemical study of amelogenin deposition during the early odontogenesis of molars in alendronate-treated newborn rats. J Histochem Cytochem 54:713–725CrossRefPubMedGoogle Scholar
McCarthy EA, Raggio CL, Hossack MD et al (2002) Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 52:660–670CrossRefPubMedGoogle Scholar
Pazianas M, Clark EM, Eiken PA et al (2013) Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. J Bone Miner Res 28:455–463. doi:10.1002/jbmr.1783CrossRefPubMedGoogle Scholar
Soares AP, do Espírito Santo RF, Line SR et al (2016) Bisphosphonates: pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development. Environ Toxicol Pharmacol 42:212–217. doi:10.1016/j.etap.2016.01.015CrossRefPubMedGoogle Scholar